Omada Health, Inc. (NASDAQ:OMDA) Given Average Recommendation of "Moderate Buy" by Analysts

Key Points

• Omada Health, Inc. has been rated as a "Moderate Buy" by analysts, with seven out of nine recommending a buy and two a hold, targeting an average price of $24.50.
• The company recently missed earnings expectations, reporting a loss of ($0.22) EPS against a consensus estimate of ($0.15) but exceeded revenue expectations with $61.37 million for the quarter.
• Significant institutional interest has been noted, with several large investors purchasing new positions in Omada Health during the second quarter, including Perceptive Advisors LLC with an investment of approximately $44.4 million.

Omada Health, Inc. (NASDAQ:OMDA - Get Free Report) has received an average rating of "Moderate Buy" from the nine ratings firms that are currently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $24.50.

OMDA has been the topic of a number of analyst reports. Robert W. Baird initiated coverage on Omada Health in a research note on Friday, September 5th. They set a "neutral" rating and a $24.00 target price on the stock. The Goldman Sachs Group assumed coverage on Omada Health in a report on Tuesday, July 1st. They set a "buy" rating and a $29.00 price objective for the company. Canaccord Genuity Group increased their target price on Omada Health from $27.00 to $28.00 and gave the stock a "buy" rating in a research note on Friday, August 8th. Barclays boosted their target price on shares of Omada Health from $21.00 to $24.00 and gave the company an "overweight" rating in a research note on Friday, August 8th. Finally, Baird R W raised shares of Omada Health to a "hold" rating in a research note on Friday, September 5th.

Institutional Trading of Omada Health

A number of large investors have recently modified their holdings of the company. Perceptive Advisors LLC bought a new position in Omada Health in the second quarter worth approximately $44,402,000. Loomis Sayles & Co. L P bought a new position in shares of Omada Health during the 2nd quarter worth $19,948,000. Sanofi bought a new position in shares of Omada Health during the 2nd quarter worth $9,606,000. Federated Hermes Inc. purchased a new position in shares of Omada Health during the second quarter valued at $9,150,000. Finally, Norges Bank bought a new stake in shares of Omada Health in the second quarter valued at about $5,490,000.

Omada Health Trading Down 0.7%

OMDA stock opened at $21.96 on Friday. Omada Health has a twelve month low of $14.14 and a twelve month high of $28.40. The company's fifty day moving average price is $20.11.

Omada Health (NASDAQ:OMDA - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.07). The firm had revenue of $61.37 million for the quarter, compared to analysts' expectations of $55.17 million. Omada Health has set its FY 2025 guidance at EPS.

Omada Health Company Profile

Omada's mission is to bend the curve. Our hope is that, one day, tomorrow's epidemiologists will notice a bend in disease curves, wonder what might be happening, and conclude that part of that impact has been Omada. As part of that mission, we strive to inspire and enable people to make lasting health changes on their own terms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.